Publicaciones en colaboración con investigadores/as de Novartis (Sweden) (14)

2016

  1. Case-only designs for studying the association of antidepressants and hip or femur fracture

    Pharmacoepidemiology and Drug Safety, Vol. 25, pp. 103-113

  2. Do case-only designs yield consistent results across design and different databases? A case study of hip fractures and benzodiazepines

    Pharmacoepidemiology and Drug Safety, Vol. 25, pp. 79-87

  3. Exposure to benzodiazepines (anxiolytics, hypnotics and related drugs) in seven European electronic healthcare databases: A cross-national descriptive study from the PROTECT-EU Project

    Pharmacoepidemiology and Drug Safety, Vol. 25, pp. 56-65

  4. Hip/femur fractures associated with the use of benzodiazepines (anxiolytics, hypnotics and related drugs): A methodological approach to assess consistencies across databases from the PROTECT-EU project

    Pharmacoepidemiology and Drug Safety, Vol. 25, pp. 66-78

  5. Multi-centre, multi-database studies with common protocols: Lessons learnt from the IMI PROTECT project

    Pharmacoepidemiology and Drug Safety, Vol. 25, pp. 156-165

  6. Prevalence of antibiotic use: A comparison across various European health care data sources

    Pharmacoepidemiology and Drug Safety, Vol. 25, pp. 11-20

  7. Risk of acute liver injury associated with use of antibiotics. Comparative cohort and nested case-control studies using two primary care databases in Europe

    Pharmacoepidemiology and Drug Safety, Vol. 25, pp. 29-38

  8. The IMI PROTECT project: Purpose, organizational structure, and procedures

    Pharmacoepidemiology and Drug Safety, Vol. 25, pp. 5-10

  9. Understanding inconsistency in the results from observational pharmacoepidemiological studies: The case of antidepressant use and risk of hip/femur fractures

    Pharmacoepidemiology and Drug Safety, Vol. 25, pp. 88-102

2015

  1. Seasonal changes in prescribing of long-acting beta-2-agonists-containing drugs

    Respiratory Medicine, Vol. 109, Núm. 7, pp. 828-837